Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy.

"Disclosure MB and KD are employees of GSK and hold stock and shares at GSK or were employees and did hold stock and shares at the time of the study. GL and AC were employees of STATinMED Research at the time of the study, which received funding from GSK to conduct the study. STATinMED Research is a business that provides consulting and other research services to pharmaceutical, device, government, and non-government organizations. STATinMED Research employees work with a variety of companies and organizations and are expressly prohibited from receiving any payment or honoraria directly from these organizations for services rendered."

"This study was funded by GSK (GSK study 214310). GSK-affiliated authors had a role in study design, data analysis, data interpretation, and writing of the report and GSK funded the article processing charges and open access fee."